References

lvrach

Лечащий Врач

Lechaschi Vrach

1560-51752687-1181

ООО «Издательство "Открытые системы"»

lvrach-700

Research Article

Статьи

Синдром поликистозных яичников — взрослая болезнь в детском возрасте: как диагностировать и лечить?

Polycystic ovary syndrome — disease of adults in childhood: methods of diagnostics and treatment

Никитина

И. Л.

Nikitina

I. L.

nikitina0901@gmail.com

Скородок

Ю. Л.

Skorodok

Yu. L.

noemail@neicon.ru

ФГБУ НМИЦ им. В. А. Алмазова МЗ РФRussian FederationФГБОУ ВО СПбГПМУ МЗ РФRussian Federation

2019

23062021

033939

2021

Никитина И.Л., Скородок Ю.Л.

Nikitina I.L., Skorodok Y.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.lvrach.ru/jour/article/view/700

Синдром поликистозных яичников (СПКЯ), достаточно хорошо изученный у взрослых, представляет значительные трудности для диагностики и лечения при дебюте в подростковом возрасте. В 2017 г. был опубликован международный консенсус, обобщивший существующую доказательную базу в отношении оказания помощи подросткам с СПКЯ. В терапии СПКЯ у подростков были рекомендованы методы немедикаментозной коррекции образа жизни; для редукции клинических симптомов гиперандрогении — локальные косметические манипуляции. Медикаментозные вмешательства должны быть ограничены применением сенситайзеров инсулина и, по показаниям, препаратов антиандрогенного действия.

Polycystic ovary syndrome (PCOS), which is sufficiently studied in adults, has significant difficulties in diagnostics and treatment when its debut falls on adolescent period. In 2017, international consensus generalizing the available base of evidence in respect of aid to adolescents with PCOS was published. As the PCOS therapy for adolescents, we recommend methods of non-drug lifestyle correction; to reduce clinical symptoms of hyper-androgynism — local cosmetic manipulations. Medical interventions must be limited by application of insulin sensitizers and, according to indications, preparations with anti-androgenic effect.

ГинекологияГиперандрогенияПодросткиСимпозиумСиндром поликистозных яичниковТерапияЭндокринология

polycystic ovary syndromehyper-androgynismadolescents

References1

Azziz R., Dumesic D. A., Goodarzi M. O. Polycystic ovary syndrome: an ancient disorder? // J Fertile Steril. 2011; 95 (5): 1544–1548. DOI: 10.1016/j.fertnstert.2010.09.032.

Azziz R., Carmina E., Chen Z., Dunaif A., Laven J. S., Legro R. S., Lizneva D., Natterson-Horowtiz B., Teede H. J., Yildiz B. O. Polycystic ovary syndrome // Nat RevDis Primers. 2016; 2: 16057. DOI: 10.1038/nrdp.2016.57.

Ibanez L., Oberfield Sh. E., Witchel S. F., Auchus R. J., Chang R. J., Codner E. et al. An international consortium apdate: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence // Horm Res Paediatr. 2017; 8896: 371–395. DOI: 10.1159/000479371.

Teede H. J., Misso M. L., Costello M. F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome // Clin Endocrinol. 2018; 89 (3): 251–268. DOI: org/10.1111/cen13795.

Marti N., Galvan J. A., Pandey A. V., Trippel M., Tapia C., Muller M. et al. genes and proteins of the alternative steroid back-door pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome // Mol Cell Endocrinol. 2017; 441: 116–123. DOI: 10.1016/j.mce.2016.07.029.

McAllister J. M., Modi B., Miller B. A., Biegler J., Bruggeman R., Legro R. S., Strauss J. F. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype // Proc Natl Acad Sci USA. 2014; 111 (15): E1519–E1527. DOI: 10.1073/pnas.1400574111.

Tee M. K., Speek M., Legeza B., Modi B., Teves M. E., McAllister J. M., Strauss J. F., Miller W. L. Alternative splicing of DENND1A, a PCOS candidate gene, generates variant 2 // Mol Cell Endocrinol. 2016; 434: 25–35. DOI: 10.1016/j.mce.2016.06.011.

Hayes M. G., Urbanek M., Ehrmann D. A., Armstrong L. L., Lee J. Y. et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations // Nat Commun. 2015; 18: 7502. DOI: 10.1038/ncomms8502.

Day F. R., Hinds D. A., Tung J. Y., Stolk L., Styrkarsdottir U., Saxena R., Bjonnes A. et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome // Nat Commun. 2015; 6: 8464. DOI: 10.1038/ncomms9464.

O’Reilly M. W., Kempegowda P., Jenkinson C., Taylor A. E., Quanson J. L., Storbeck K. H., Arlt W. 11-oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome // J Clin Endocrinol Metab. 2017; 102 (3): 840–848. DOI: 10.1210/jc.2016–3285.

Geffner M. E., Golde D. W. Selective insulin action on skin, ovary, and heart in insulin-resistant states // Diabetes Care. 1988; 11 (6): 500–505. DOI: 10.2337/diacare.11.6.500.

Wu H. L., Heneidi S., Chuang T. Y., Diaond M. P., Layman L. C., Azziz R., Chen Y. H. The expression of the miR-25/93/106b family of micro- RNAs in the adipose tissue of women with polycystic ovary syndrome // J Clin Endocrinol Metab. 2014; 99 (12): E2754–E2761. DOI: 10.1210/jc.2013–4435.

Song J., Luo S., Li S. W. miRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients // Reprod Biol. 2015; 15 (4): 229–237. DOI: 10.1016/j.repbio.2015.10.005.

Pediatric and adolescent gynecology: evidence-basedclinical practice/ed. Sultan C., 2nd, revised and extendededition. Endocr Dev. Basel, Karger, 2012, Vol. 22, p. 181–193.

Apter D. Endocrine and metabolic abnormalities in adolescents with a PCOS-like condition: consequences for adult reproduction // Trends Endocrinol Metab. 1998; 9: 58–61. DOI: 10.1016/S1043–2760(98)00020–4.

Hickey M., Doherty D. A., Atkinson H., Sloboda D. M., Franks S., Norman R. J., Hart R. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis // Hum Reprod. 2011; 26: 1469–1477.

Никитина И. Л. Йоддефицитные заболевания у детей Забайкалья. Автореф. дисс. к. м.н. Томск, 2000.

Никитина И. Л. Особенности йоддефицитных заболеваний у детей Забайкальского региона. Автореф. дис. … д-ра мед наук. М.: 2002; 48 с.

Щербак В. А., Ильина Н. Н, Гаймоленко И. Н., Тихоненко О. А., Емельянова О. Н., Никитина И. Л. и др. Детские болезни. Учебник для врачей-педиатров первичного звена здравоохранения. Чита: Читинская государственная медицинская академия, 2008.

Никитина И. Л., Тодиева А. М., Каронова Т. Л., Гринева Е. Н. К вопросу о метаболических нарушениях у детей со сниженным уровнем витамина D и ожирением // Лечащий Врач. 2014; 3: 10–14.

Sinha R., Fisch G., Teague B., Tamborlane W. V., Banyas B., Allen K. et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity // N Engl J Med. 2002; 346 (11): 802–810. DOI: 10.1056/NEJMoa012578.

Ferriman D., Gallwey J. D. Clinical assessment of body hair growth in women // J Clin Endocrinol Metab. 1961; 21: 1440–1447.

Engmann L., Jin S., Sun F., Legro R. S., Polotsky A. J., Hansen K. R. et al Reproductive Medicine Network: Racial and ethnic differences in the polycystic ovary syndrome (PCOS) metabolic phenotype // Am J Obstet Gynecol. 2017; 216 (5): 493.e1–e13. DOI: 10.1016/j.ajog.2017.01.003.

Y?ld?z B. O., Bolour S., Woods K., Moore A., Azziz R. Visually scoring hirsutism // Hum Reprod Update. 2010; 16 (1): 51–64. DOI: 10.1093/humupd/dmp024.

Chen W. C., Zouboulis C. C. Hormones and the pilosebaceous unit // Dermatoendocrinol. 2009; 1 (2): 81–86.

Merino P. M., Codner E., Cassorla F. A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence // Arq Bras Endocrinol Metabol. 2011; 55 (8): 590–598.

Witchel S. F., Oberfield S., Rosenfield R. L., Codner E., Bonny A., Ibanez L. et al. The diagnosis of polycystic ovary syndrome during adolescence // Horm Res Paediatr. 2015; 83: 376–389. DOI: 10.1159/000375530.

Gambineri A., Fanelli F., Prontera O., Repaci A., Di Dalmazi G., Zanotti L. et al. Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on Italian high-school students // J Clin Endocrinol Metab. 2013; 98 (4): 1641–1650.

Sarray S., Almawi W. Y. Levels of CD40L and other inflammatory biomarkers in obese and non-obese women with polycystic ovary syndrome // Am J Reprod Immunol. 2016; 76: 285–291.

Li Li, Zhang J., Deng Q., Li J., Li Z., Xiao Y. et al. Proteomic profiling for identification of novel biomarkers differentially expressed in human ovaries from polycystic ovary syndrome patients // PLoS One. 2016; 11: e0164538.

Lie Fong S., Visser J. A., Welt C. K., de Rijke Y. B., Eijkemans M. J., Broekmans F. J. et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood // J Clin Endocrinol Metab. 2012; 97 (12): 4650–4655. DOI: 10.1210/jc.2012–1440.

Munzker J., Hofer D., Trummer C., Ulbing M., Harger A., Pieber T. et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome // J Clin Endocrinol Metab. 2015; 100 (2): 653–660. DOI: 10.1210/jc.2014–2523.

Villarroel C., Merino P. M., Lopez P., Eyzaguirre F. C., Van Velzen A., Iniguez G., Codner E. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone // Hum Reprod. 2011; 26: 2861–2868.

Hierro F., Marcos M. V., de Zegher F. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism // J Clin Endocrinol Metab. 2002; 87 (12): 5702–5705. DOI: 10.1097/00006254–200305000–00017.

Ibanez L., Valls C., Ferrer A., Marcos M. V., Rodriguez-Hierro F., de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism // J Clin Endocrinol Metab. 2001; 86 (8): 3595–3598. doi.org/10.1210/jcem.86.8.7756.

Ganie M. A., Khurana M. L., Eunice M., Gupta N., Gulati M., Dwivedi S. N., Ammini A. C. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study // J Clin Endocrinol Metab. 2004; 89 (6): 2756–2762. DOI: 10.1210/jc.2003–031780.

Mastorakos G., Koliopoulos C., Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives // Fertil Steril. 2002; 77: 919–927.

Mastorakos G., Koliopoulos C., Deligeoroglou E., Diamanti-Kandarakis E., Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome // Fertil Steril. 2006; 85: 420–427

The authors declare that there are no conflicts of interest present.